28 related articles for article (PubMed ID: 32718298)
1. Relationships between Osteopontin, Osteoprotegerin, and Other Extracellular Matrix Proteins in Calcifying Arteries.
Kuzan A; Chwiłkowska A; Maksymowicz K; Abramczyk U; Gamian A
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672202
[TBL] [Abstract][Full Text] [Related]
2. Role of the Hypoxic-Secretome in Seed and Soil Metastatic Preparation.
Clemente-González C; Carnero A
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497411
[TBL] [Abstract][Full Text] [Related]
3. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
4. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
5. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
[TBL] [Abstract][Full Text] [Related]
6. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression.
Castellano G; Malaponte G; Mazzarino MC; Figini M; Marchese F; Gangemi P; Travali S; Stivala F; Canevari S; Libra M
Clin Cancer Res; 2008 Nov; 14(22):7470-80. PubMed ID: 19010864
[TBL] [Abstract][Full Text] [Related]
7. The key role of proinflammatory cytokines, matrix proteins, RANKL/OPG and Wnt/β-catenin in bone healing of hip arthroplasty patients.
Cassuto J; Folestad A; Göthlin J; Malchau H; Kärrholm J
Bone; 2018 Feb; 107():66-77. PubMed ID: 29129760
[TBL] [Abstract][Full Text] [Related]
8. Implication of Prophetic Variables and their Impulsive Interplay in CA Prostate Patients Experiencing Osteo-Metastasis.
Ashraf MAB; Zahid A; Ashraf S; Waquar S; Iqbal S; Malik A
Anticancer Agents Med Chem; 2020; 20(17):2106-2113. PubMed ID: 32718298
[TBL] [Abstract][Full Text] [Related]
9. The role of osteoclastic activity in prostate cancer skeletal metastases.
Keller ET
Drugs Today (Barc); 2002 Feb; 38(2):91-102. PubMed ID: 12532187
[TBL] [Abstract][Full Text] [Related]
10. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment.
Koeneman KS; Yeung F; Chung LW
Prostate; 1999 Jun; 39(4):246-61. PubMed ID: 10344214
[TBL] [Abstract][Full Text] [Related]
11. [Cytokines as markers of osteolysis in the diagnostics of patients with bone metastases].
Groblewska M; Mroczko B; Czygier M; Szmitkowski M
Postepy Hig Med Dosw (Online); 2008 Dec; 62():668-75. PubMed ID: 19188882
[TBL] [Abstract][Full Text] [Related]
12. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone.
Keller ET; Zhang J; Cooper CR; Smith PC; McCauley LK; Pienta KJ; Taichman RS
Cancer Metastasis Rev; 2001; 20(3-4):333-49. PubMed ID: 12085970
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
